178 related articles for article (PubMed ID: 21780109)
1. Expression of the nuclear bile acid receptor/farnesoid X receptor is reduced in human colon carcinoma compared to nonneoplastic mucosa independent from site and may be associated with adverse prognosis.
Lax S; Schauer G; Prein K; Kapitan M; Silbert D; Berghold A; Berger A; Trauner M
Int J Cancer; 2012 May; 130(10):2232-9. PubMed ID: 21780109
[TBL] [Abstract][Full Text] [Related]
2. Farnesoid X receptor expression is decreased in colonic mucosa of patients with primary sclerosing cholangitis and colitis-associated neoplasia.
Torres J; Bao X; Iuga AC; Chen A; Harpaz N; Ullman T; Cohen BL; Pineton de Chambrun G; Asciutti S; Odin JA; Sachar DB; Gaskins HR; Setchell K; Colombel JF; Itzkowitz SH
Inflamm Bowel Dis; 2013 Feb; 19(2):275-82. PubMed ID: 23348121
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of Adenomatous Polyposis Coli Reduces Bile Acid/Farnesoid X Receptor Expression through Fxr gene CpG Methylation in Mouse Colon Tumors and Human Colon Cancer Cells.
Selmin OI; Fang C; Lyon AM; Doetschman TC; Thompson PA; Martinez JD; Smith JW; Lance PM; Romagnolo DF
J Nutr; 2016 Feb; 146(2):236-42. PubMed ID: 26609171
[TBL] [Abstract][Full Text] [Related]
4. FXR silencing in human colon cancer by DNA methylation and KRAS signaling.
Bailey AM; Zhan L; Maru D; Shureiqi I; Pickering CR; Kiriakova G; Izzo J; He N; Wei C; Baladandayuthapani V; Liang H; Kopetz S; Powis G; Guo GL
Am J Physiol Gastrointest Liver Physiol; 2014 Jan; 306(1):G48-58. PubMed ID: 24177031
[TBL] [Abstract][Full Text] [Related]
5. Src-mediated cross-talk between farnesoid X and epidermal growth factor receptors inhibits human intestinal cell proliferation and tumorigenesis.
Peng Z; Raufman JP; Xie G
PLoS One; 2012; 7(10):e48461. PubMed ID: 23119029
[TBL] [Abstract][Full Text] [Related]
6. microRNA-192 suppresses the expression of the farnesoid X receptor.
Krattinger R; Boström A; Schiöth HB; Thasler WE; Mwinyi J; Kullak-Ublick GA
Am J Physiol Gastrointest Liver Physiol; 2016 Jun; 310(11):G1044-51. PubMed ID: 27079614
[TBL] [Abstract][Full Text] [Related]
7. Localization and expression of p27KIP1 in multistage colorectal carcinogenesis.
Ciaparrone M; Yamamoto H; Yao Y; Sgambato A; Cattoretti G; Tomita N; Monden T; Rotterdam H; Weinstein IB
Cancer Res; 1998 Jan; 58(1):114-22. PubMed ID: 9426067
[TBL] [Abstract][Full Text] [Related]
8. Farnesoid X receptor represses matrix metalloproteinase 7 expression, revealing this regulatory axis as a promising therapeutic target in colon cancer.
Peng Z; Chen J; Drachenberg CB; Raufman JP; Xie G
J Biol Chem; 2019 May; 294(21):8529-8542. PubMed ID: 30967475
[TBL] [Abstract][Full Text] [Related]
9.
Romagnolo DF; Donovan MG; Doetschman TC; Selmin OI
Nutrients; 2019 Jan; 11(1):. PubMed ID: 30650553
[TBL] [Abstract][Full Text] [Related]
10. Bile acids and colon cancer: Is FXR the solution of the conundrum?
Gadaleta RM; Garcia-Irigoyen O; Moschetta A
Mol Aspects Med; 2017 Aug; 56():66-74. PubMed ID: 28400119
[TBL] [Abstract][Full Text] [Related]
11. Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development.
Maran RR; Thomas A; Roth M; Sheng Z; Esterly N; Pinson D; Gao X; Zhang Y; Ganapathy V; Gonzalez FJ; Guo GL
J Pharmacol Exp Ther; 2009 Feb; 328(2):469-77. PubMed ID: 18981289
[TBL] [Abstract][Full Text] [Related]
12. The bile acid nuclear receptor FXR and the bile acid binding protein IBABP are differently expressed in colon cancer.
De Gottardi A; Touri F; Maurer CA; Perez A; Maurhofer O; Ventre G; Bentzen CL; Niesor EJ; Dufour JF
Dig Dis Sci; 2004 Jun; 49(6):982-9. PubMed ID: 15309887
[TBL] [Abstract][Full Text] [Related]
13. Impaired Intestinal Farnesoid X Receptor Signaling in Cystic Fibrosis Mice.
Ikpa PT; Doktorova M; Meijsen KF; Nieuwenhuijze NDA; Verkade HJ; Jonker JW; de Jonge HR; Bijvelds MJC
Cell Mol Gastroenterol Hepatol; 2020; 9(1):47-60. PubMed ID: 31470114
[TBL] [Abstract][Full Text] [Related]
14. Tissue-specific function of farnesoid X receptor in liver and intestine.
Zhu Y; Li F; Guo GL
Pharmacol Res; 2011 Apr; 63(4):259-65. PubMed ID: 21211565
[TBL] [Abstract][Full Text] [Related]
15. FXR agonist GW4064 improves liver and intestinal pathology and alters bile acid metabolism in rats undergoing small intestinal resection.
Cao Y; Xiao Y; Zhou K; Yan J; Wang P; Yan W; Cai W
Am J Physiol Gastrointest Liver Physiol; 2019 Aug; 317(2):G108-G115. PubMed ID: 30920307
[TBL] [Abstract][Full Text] [Related]
16. Nuclear bile acid receptor FXR protects against intestinal tumorigenesis.
Modica S; Murzilli S; Salvatore L; Schmidt DR; Moschetta A
Cancer Res; 2008 Dec; 68(23):9589-94. PubMed ID: 19047134
[TBL] [Abstract][Full Text] [Related]
17. MiR-22-silenced cyclin A expression in colon and liver cancer cells is regulated by bile acid receptor.
Yang F; Hu Y; Liu HX; Wan YJ
J Biol Chem; 2015 Mar; 290(10):6507-15. PubMed ID: 25596928
[TBL] [Abstract][Full Text] [Related]
18. Bile salt supplementation acts via the farnesoid X receptor to alleviate lipopolysaccharide-induced intestinal injury.
Zahiri HR; Perrone EE; Strauch ED
Surgery; 2011 Sep; 150(3):480-9. PubMed ID: 21878234
[TBL] [Abstract][Full Text] [Related]
19. Farnesoid X receptor agonists attenuate colonic epithelial secretory function and prevent experimental diarrhoea in vivo.
Mroz MS; Keating N; Ward JB; Sarker R; Amu S; Aviello G; Donowitz M; Fallon PG; Keely SJ
Gut; 2014 May; 63(5):808-17. PubMed ID: 23916961
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like peptide 1 analogue prevents cholesterol gallstone formation by modulating intestinal farnesoid X receptor activity.
Zhang Z; Du Z; Liu Q; Wu T; Tang Q; Zhang J; Huang C; Huang Y; Li R; Li Y; Zhao Y; Zhang G; Zhou J; Huang H; Fang Z; He J
Metabolism; 2021 May; 118():154728. PubMed ID: 33581130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
